- Global Pharma News & Resources

DXC Technology Opens Digital Innovation Lab in Singapore

DXC Technology (NYSE: DXC), the world’s leading independent, end-to-end IT services company, today announced the opening of the DXC Digital Innovation Lab in Singapore.

Developed with the support of the Singapore Economic Development Board (EDB), the DXC Digital Innovation Lab Singapore is an advanced environment for the incubation of ideas, learning and innovative technology solutions developed by data scientists and enterprise solution experts. The lab will benefit DXC employees, clients and partners, as well as the technology and business communities of Singapore, the region and beyond.

The DXC Digital Innovation Lab Singapore is an extension of DXC Labs, whose goal is to ensure that DXC masters the emerging technologies it needs in order to lead clients through accelerating digital transformation. At the innovation lab, digital specialists will explore novel technologies, develop prototypes and create reference architectures for rapid business deployment. It will showcase new and evolving approaches for delivering transformative digital solutions in industries such as insurance and financial services, healthcare and manufacturing. DXC Digital Innovation Lab Singapore will enable DXC to co-create prototypes and solutions with customers and partners across Asia.

“The DXC Digital Innovation Lab will accelerate the digital transformation of enterprises in Singapore,” said Ang Chin Tah, director of Infocomms and Media, EDB. “The Lab will also create opportunities for Singaporeans to gain valuable practical experience from the use of cutting-edge technology in real-life business applications, further building our pipeline of commercially-minded digital talent.”

Organizations are increasingly recognizing the need to disrupt and digitally transform. In a recent HBR Analytic Services survey, 79 percent of respondents said their organizations must go through substantial or extensive change to become even more digital over the next few years.

“The DXC Digital Innovation Lab Singapore positions DXC Asia at the core of innovation; using advanced technologies and best practices, we localize solutions to address the unique requirements of our clients,” said Koushik Radhakrishnan, vice president and general manager, DXC Technology Asia.

“With over 40 years of experience in Singapore and Asia, DXC is laser-focused on enabling digital transformation in this rapidly growing region through iterative development, minimally viable products, customer co-creation and user-centric design,” he added.

The DXC Digital Innovation Lab Singapore will help address customer business challenges and deliver transformative industry outcomes leveraging emerging technologies such as machine learning, artificial intelligence, IoT, blockchain and humanoid robotics.

Innovations on display at the DXC Digital Innovation Lab Singapore include:

  • Artificial Intelligence (AI) Aid for Antibiotics Prescribing – According to a recent article Antibiotic Prescribing: Attitudes, Behaviors, Trends and Cost (2018), published by the U.S. Centers for Disease Control and Prevention, more than 30 percent of antibiotics are over-prescribed in outpatient scenarios. Using data analytics and advanced algorithms, DXC and the Singapore General Hospital (SGH) are working on an AI solution that can guide a doctor in prescribing antibiotics. This solution has recently been recognized as one of the most impactful projects, by the Ministry of Health, Singapore at the “National Health Tech Challenge” awards.
  • Humanoid Robotics for Digital Collaboration – Using advanced mobile applications and humanoid robotics technologies, this DXC solution highlights the future of digital collaboration between enterprises, customers and other stakeholders relevant to the insurance industry today. Supported by the application of machine learning/artificial intelligence (ML/AI), the humanoid robot agent helps banks or wealth managers recommend and sell insurance solutions personalized for each customer. It also allows insurers to interact and complete the insurance solutions sale process through this platform. The interaction is directly with the customer, thereby giving transparent and authentic data based on vital image statistics from the robot.

“The prescription of antibiotics globally, including in Singapore, is largely reliant on the doctors’ clinical experience and sharp diagnostic sense. This could potentially give rise to inconsistent practice and patient outcomes, especially in local hospitals with high patient volume, where we need to diagnose fast,” said Dr. Andrea Kwa, pharmacy clinician-scientist, Singapore General Hospital, which has also collaborated with DXC on this project.

“The use of artificial intelligence will augment diagnostic acumen to guide appropriate antibiotics prescribing in such a highly stressed clinical environment, and thus complement antibiotic stewardship efforts,” he added.

About DXC Technology

DXC Technology (NYSE: DXC) is the world's leading independent, end-to-end IT services company, serving nearly 6,000 private and public-sector clients from a diverse array of industries across 70 countries. The company's technology independence, global talent and extensive partner network deliver transformative digital offerings and solutions that help clients harness the power of innovation to thrive on change. DXC Technology is recognized among the best corporate citizens globally. For more information, visit

View source version on

Editor Details

Last Updated: 25-Oct-2018